Hybridoma cell strain and antibody for detecting rituximab and biosimilar drugs thereof and application of hybridoma cell strain and antibody
CN119570743AActive Publication Date: 2025-03-07BEIJING DIAGREAT BIOTECH CO LTD
Patent Information
- Application Number
- CN202510134590.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-02-07
- Publication Date
- 2025-03-07
- Estimated Expiration
- 2045-02-07
Smart Images
Figure FT_1 
Figure FT_2 
Figure SMS_1
Abstract
The invention relates to a hybridoma cell strain for detecting rituximab and biosimilar drugs thereof, an antibody and application thereof, and belongs to the technical field of biological detection. The hybridoma cell strain provided by the invention is a hybridoma cell strain combination and comprises a hybridoma cell strain RTX-9C02 and a hybridoma cell strain RTX-5B12 which can secrete monoclonal antibodies which are specifically combined with rituximab; the generated monoclonal antibodies RTX-9C02 and RTX-5B12 can be combined for detecting the blood concentration of the rituximab and the biologically similar drugs thereof, and the effect of stably, accurately and highly specifically detecting the rituximab and the biologically similar drugs thereof is achieved.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Pharmacokinetic research mass spectrometry method for rituximab
CN111239273A
Artificial antigen and kit for rituximab blood concentration detection
CN112661816A
Rituximab similar drug double-antibody sandwich ELISA quantitative kit and application thereof
CN115902235A
Hybridoma cell strain combination and antibody combination for detecting adalimumab and application of hybridoma cell strain combination and antibody combination
CN117003870A
Hybridoma cell strain combination and antibody combination for detecting goalimumab and application of hybridoma cell strain combination and antibody combination
CN117003882A